Navigation Links
UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
Date:9/4/2007

Charlottesville, Va., September 4, 2007 A University of Virginia researcher has been awarded a $3.6 million grant from the National Institute of Allergy and Infectious Diseases to combat a growing international health crisis.

Dr. Richard Guerrant, founder of UVas Center for Global Health, plans to take a unique approach to treating the bacterium Clostridium difficile, which is growing increasingly resistant to certain antibiotics that work against bacteria of the colon. Clostridium difficile (C. diff) is a bacterium that causes diarrhea and can lead to more serious intestinal conditions such as colitis.

This is a huge problem which has been getting worse since the mid-1980s. Previously healthy young people are becoming ill with the disease and the national mortality rate from the disease has more than doubled in the last few years, Guerrant says.

Patients who are most at risk from C. diff have traditionally been older or have taken antibiotics for an extended period of time. The antibiotics eradicate the beneficial bacteria which all people have in their digestive tract, leaving the drug resistant C. diff to flourish. An estimated 5 to 7 percent of residents of assisted living and nursing facilities are infected with the bacterium.

The Centers for Disease Control reports there have been C. diff outbreaks in hospitals in 23 states. The drug-resistant strain has been blamed for more than 100 deaths over an 18-month period at a hospital in Quebec. The bacteria are found in feces. Infection can occur when people touch items or surfaces contaminated with feces.

C. difficile produces two toxins which cause the body to react with diarrhea, fever, loss of appetite, nausea and abdominal pain. Because the bacterium is proving resistant to antibiotics, Guerrant proposes countering the effects of the toxins instead of targeting the bacterium.

The current treatments have been to try a new antibiotic on the bacterium, which kills even more of the beneficial bacteria and allows C. diff to continue ravaging the patients, Guerrant says. By rendering the toxins harmless, we hope we can keep the debilitating effects of C. diff from proving fatal.

Guerrant says pilot data show this approach has great promise and he plans to collaborate with other UVa scientists and a pharmaceutical company to develop the treatment.


'/>"/>

Contact: David Foreman
davidforeman@virginia.edu
434-924-2242
University of Virginia Health System
Source:Eurekalert

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
4. New Hair in 15 Days Could Now Be A Possibility Say Researchers
5. Researchers at Cornell University as been reported using research fund by false claims
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. Gene researchers make Malaria-resistant mosquito
9. Researchers developed world’s smallest toothbrus
10. Researchers discover receptor cells that can cause epilepsy
11. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... ... organ prolapse with the latest techniques and the most minimally invasive approaches. , ... organ prolapse, particularly after menopause. Other risk factors include surgery to the pelvic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... sector has been slower than other industries to embrace ... that come with utilization. On the medical side, organizations ... to improve everything from clinical trials to adherence. ... recent research from benchmarking firm Best Practices, LLC, Big ...
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: ... Annual Global Healthcare Conference at 9:15 a.m. ET on ... . David W. Meline , executive vice president ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
(Date:2/5/2016)...  Redwood Scientific Technologies, Inc. announced today the development ... women balance their hormones. This product will be featuring ... Jason Cardiff , President and CEO. "I am proud ... millions of women across the country and around the ... Our research and development team is confident that through ...
Breaking Medicine Technology: